Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Update

Atossa Genetics Inc. (NASDAQ:ATOS) saw a significant increase in short interest in December. As of December 15th, there was short interest totaling 2,284,050 shares, an increase of 47.0% from the November 30th total of 1,554,063 shares. Currently, 1.9% of the company’s stock are short sold. Based on an average trading volume of 1,461,615 shares, the short-interest ratio is presently 1.6 days. Based on an average trading volume of 1,461,615 shares, the short-interest ratio is presently 1.6 days. Currently, 1.9% of the company’s stock are short sold.

Atossa Genetics Price Performance

NASDAQ ATOS opened at $0.66 on Tuesday. The company has a market cap of $85.07 million, a price-to-earnings ratio of -2.74 and a beta of 0.95. The stock’s fifty day moving average price is $0.80 and its 200 day moving average price is $0.83. Atossa Genetics has a 1 year low of $0.55 and a 1 year high of $1.29.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). Research analysts expect that Atossa Genetics will post -0.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Zacks Research downgraded Atossa Genetics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Ascendiant Capital Markets upped their target price on Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Atossa Genetics has an average rating of “Hold” and a consensus target price of $6.33.

Institutional Investors Weigh In On Atossa Genetics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd acquired a new stake in Atossa Genetics during the second quarter worth about $321,000. Charles Schwab Investment Management Inc. lifted its holdings in Atossa Genetics by 40.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company’s stock valued at $284,000 after acquiring an additional 120,934 shares during the period. Nuveen LLC purchased a new stake in Atossa Genetics in the 1st quarter worth approximately $115,000. Gallagher Capital Advisors LLC acquired a new stake in shares of Atossa Genetics during the 3rd quarter worth approximately $27,000. Finally, GSA Capital Partners LLP increased its holdings in shares of Atossa Genetics by 509.0% during the 3rd quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock valued at $269,000 after purchasing an additional 259,725 shares in the last quarter. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.